Nature Reviews Urology **12**, 301 (2015); published online 12 May 2015;
doi:10.1038/nrurol.2015.107;
doi:10.1038/nrurol.2015.108;
doi:10.1038/nrurol.2015.109;
doi:10.1038/nrurol.2015.110

IN BRIEF

UROLOGIC ONCOLOGY

***Moringa oleifera* leaf for chemotherapy-induced infertility**

Administration of *Moringa oleifera* leaf extract might be beneficial in reducing the toxic effects of chemotherapy on male gonadal function, according to a new study. Nayak *et al.* investigated the effect of *Moringa oleifera* leaf extract on cyclophosphamide-induced testicular toxicity in 2-week-old mice. Cyclophosphamide injections resulted in a decline in sperm motility, an increase in sperm head abnormality and an increase in sperm DNA damage, but co-administration of *Moringa oleifera* leaf extract mitigated these effects.

Original article Nayak, G. *et al.* Sperm abnormalities induced by pre-pubertal exposure to cyclophosphamide are effectively mitigated by *Moringa oleifera* leaf extract. *Andrologia* doi:10.1111/and.12422

PROSTATE CANCER

Absorbable spacers in men undergoing prostate IG-IMRT

Implantation of an absorbable perirectal spacer is associated with decreased rectal irradiation, decreased severity of rectal toxicity and reduced rates of bowel problems in patients with clinical stage T1 or T2 prostate cancer undergoing image-guided intensity-modulated radiotherapy (IG-IMRT), say researchers. Mariados and co-workers' study involved 222 patients randomly assigned to either spacer implantation or no implantation who underwent IG-IMRT and were followed up over 15 months.

Original article Mariados, N. *et al.* Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate IG-IMRT. *Int. J. Radiat. Oncol. Biol. Phys.* doi:10.1016/j.ijrobp.2015.04.030

MALE FACTOR INFERTILITY

HCG-based therapy for testosterone-related infertility

Combination therapy with human chorionic gonadotropin (HCG) and supplemental medications (such as tamoxifen and anastrozole) might be useful in treating men with azoospermia or severe oligospermia caused by testosterone supplementation. Wenker's study included 49 men, 47 of whom showed return of spermatogenesis or improved sperm counts with combination HCG therapy; in addition, the partner of one patient without follow-up semen analysis had a documented pregnancy.

Original article Wenker, E. P. *et al.* The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. *J. Sex. Med.* doi:10.1111/jsm.12890

INCONTINENCE

BoNT-A injections in patients with detrusor overactivity

Researchers in Taiwan report that 1 ml injections of intravesical onabotulinumtoxinA (BoNT-A) at 10 sites is enough to result in good therapeutic effect in patients with detrusor overactivity. In their study involving 67 patients randomly assigned to receive 10 injections, 20 injections or 40 injections, Liao and co-workers found that rates of successful treatment (defined as a global response assessment ≥ 1 after treatment) were similar in the three groups at 1 month, 3 months and 6 months.

Original article Liao, C.-H. *et al.* Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. *NeuroUrol. Urodyn.* doi:10.1002/nau.22780